Zantac patent appellate court ruling expected by end of March.
This article was originally published in The Tan Sheet
GLAXO/NOVOPHARM ZANTAC APPEAL DECISION LIKELY BY MARCH, based on the expedited handling being given by the D.C. federal appeals court to the patent case for the H2 antagonist. Although no schedule has been set by the court, Novopharm said it expects oral arguments in December or January and the court to render its decision by the end of March. Glaxo is appealing a Raleigh, N.C. federal court ruling that would allow Novopharm to launch a generic version of the prescription ulcer medication ranitidine (Form 1) in July 1997 ("The Tan Sheet" July 15, p. 5).
You may also be interested in...
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning